Cue Biopharma has appointed James Ahlers as its new Chief Financial Officer, effective July 30, 2026. Mr. Ahlers brings extensive financial leadership experience from numerous public and private life sciences companies, including nearly two decades as CFO of Intarcia Therapeutics.
Key Details
- Appointment: James Ahlers was appointed Chief Financial Officer and principal financial officer, effective July 30, 2026.
- Compensation: The employment agreement includes a $450,000 annual base salary and a target annual bonus of up to 45% of his base salary.
- Inducement Grants: Mr. Ahlers received inducement grants consisting of options to purchase 51,000 shares of common stock and a restricted stock unit (RSU) award for 25,500 shares, both vesting over four years.